Julie M. Vose, MD, MBA

The FDA approval of zanubrutinib plus obinutuzumab showed a benefit to patients with relapsed/refractory follicular lymphoma, according to Julie Vose, MD, MBA.

Julie M. Vose, MD, MBA, discusses the pros and cons of patients having early access to electronic medical records.

Julie M. Vose, MD, MBA, discussed the use of collaboration in driving progress in mantle cell lymphoma research and bridging the gap between research and clinical care.

Julie M. Vose, MD, MBA, gave a brief overview of the 2023 American Society of Hematology Annual Meeting & Exposition, as well as what to be on the lookout for in 2024.

The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.

Julie M. Vose, MD, MBA, looks back at 2023 on accomplishments and setbacks surrounding the heamtology/oncology space.

Dose adjustments and alternative treatment regimens may be required amid hematologic drug shortages.

Julie M. Vose, MD, MBA, reflects on the generic drug shortages and the reasoning behind the continued pattern affecting different cancer types.

Julie M. Vose, MD, MBA, discussed why the need for multidisciplinary care is so pertinent, and how it must continue even after treatment ends.

Avyakta Kallam, MBBS and Julie Vose MD, MBA, review available treatment options for patients with mantle cell lymphoma.

In the August Letter to Readers, Julie M. Vose, MD, MBA, discusses the recent cisplatin shortages and how this can be mitigated in the future.

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the optimal ways to manage short- and long-term toxicities associated with cancer.

Co-editor-in-Chief Julie M. Vose, MD, MBA, writes about the effects and prevalence of burnout amongst oncologists and reviews strategies to address the issue.

Co-editor-in-Chief Julie M. Vose, MD, MBA, reviews the most prominent developments from the 64th Annual Meeting of the American Society of Hematology.

In her Letter to the Readers, co-editor-in-chief of the journal ONCOLOGY Julie M. Vose, MD, MBA, reviews developments from the fourth annual LEAD Conference for women in hematology and oncology.

ONCOLOGY Co-Editor-in-Chief Julie M. Vose, MD, MBA, explores high drug costs and financial toxicity.

In this month's Letter to the Readers, ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MDA, dives into the topic of survivorship care.

Julie M. Vose, MD, MBA, chief of Hematology/Oncology at the Buffett Cancer Center of the University of Nebraska Medical Center, writes about American Board of Internal Medicine Recertification Exams in her monthly "Letter to the Readers."

ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, re-caps the 2021 American Society of Hematology conference and discusses which presentations were the most important.

ONCOLOGY co-editor-in-chief Julie M. Vose, MD, MBA, anticipates how COVID-19 will continue to impact the oncology field.

ONCOLOGY® co-editor-in-chief Julie M. Vose, MD, MBA, recaps the 2021 Leadership, Empowerment, and Development Conference: Enriching and Supporting Women in Hematology and Oncology.

ONCOLOGY® co–editor-in-chief, Julie Vose, discusses how the COVID-19 pandemic has caused physician burnout and what may be done to prevent it.

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center, discusses novel treatment options for patients with hematologic malignancies at the 2021 American Society of Clinical Oncology Annual Meeting.

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.

CancerNetwork® sat down with Julie Vose, MD, MBA, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about a clinical trial comparing acalabrutinib versus ibrutinib for patients with chronic lymphocytic leukemia.

ONCOLOGY® co-Editor-in-Cheif Julie M. Vose, MD, MBA, chief of the Division of Hematology/Oncology at the University of Nebraska Medical Center in Omaha, Nebraska, discusses the emergence of telehealth during the COVID-19 pandemic and the needs of patients going forward.

Co-Editor in Chief of the journal ONCOLOGY discusses how potential shortages in oncology clinicians could influence the treatment of cancer going forward.

ONCOLOGY co–Editor-in-Chief Julie M. Vose, MD, MBA, details how underrepresentation of racial and ethnic minorities in clinical trials negatively impacts the medical community and calls for greater inclusion by removing some barriers to participation.

Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.

The 2020 American Society of Hematology Meeting and Exposition included several exciting presentations and promising data for patients with various hematologic malignncies.